A Phase 1 interventional study of BLX-7006 and Placebo in Normal Healthy Volunteer and Safety After Oral Intake, sponsored by Biolexis Therapeutics. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Biolexis Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.
Among the 187 studies in Obesity with a site in Australia, this one is the 109th largest by planned enrollment of the 168 interventional ones that give a count, is one of 25 that started in 2025, is one of 32 in phase 1, reaches primary completion later than 8 of the 73 other live ones, and was the 138th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →56 of the 187 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Australia, United States, Canada and 2 more countries
Ages 18–99
Verdiva Bio Dev Limited · Sites in Australia
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 34 · Phase 3 59 · Phase 4 8
First in 1995; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 184 across the 168 interventional studies, 626 across the 19 observational. Of the 96 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 187 have an industry lead sponsor. The 10 most frequent:
Biolexis Therapeutics is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Biolexis Therapeutics has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
24 of the studies in Obesity with a site in Australia that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 24 to your calendar (.ics) → With an account.
Among the 187 studies in Obesity with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.
This is a Phase 1, single-center, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the effect of food on the PK of BLX-7006, a novel oral small-molecule GLP-1 receptor agonist, in healthy adult volunteers. The study consists of three parts: single ascending dose (SAD), food effect (FE), and multiple ascending dose (MAD) assessments.
Study Rationale and Objectives:
BLX-7006 is being developed as an oral alternative to currently available injectable GLP-1 receptor agonists used for the treatment of metabolic diseases such as type 2 diabetes mellitus and obesity. Oral delivery of BLX-7006 may improve convenience and treatment adherence while maintaining the metabolic benefits of GLP-1 agonism. This Phase 1 study is designed to characterize the initial safety profile, define the PK properties of BLX-7006, evaluate preliminary PD biomarkers of glucose metabolism, and determine the impact of a high-fat meal on drug absorption.
Study Design Overview:
The study will enroll approximately 76 healthy adults across three sequential parts.
Part 1: Single Ascending Dose (SAD) This is a randomized, double-blind, placebo-controlled, sequential SAD study in up to four cohorts (approximately 8 participants per cohort; 6 active, 2 placebo). Doses will escalate sequentially following review of blinded safety, tolerability, PK, and PD data by a Safety Review Committee (SRC). A sentinel dosing approach will be used for each cohort (1 active, 1 placebo) prior to dosing the remainder of the cohort. Participants will be confined in the clinical research unit (CRU) for approximately 4 days for safety monitoring, PK and PD blood sampling, and will return for an end-of-study (EOS) visit on Day 8. SAD data will inform dose selection for the FE and MAD parts of the study.
Part 2: Food Effect (FE) This is an open-label, randomized, 2-period, 2-sequence crossover study designed to evaluate the effect of a high-fat, high-calorie meal on the PK of a single oral dose of BLX-7006. A single cohort of 12 participants will receive BLX-7006 under both fasted and fed conditions, with a 7-day washout between doses. Participants will be confined for approximately 4 days in each period, with safety, PK, and PD assessments performed throughout. The SRC may adjust the washout interval or timing of assessments based on PK results from the SAD cohorts to ensure adequate elimination between periods.
Part 3: Multiple Ascending Dose (MAD) This is a randomized, double-blind, placebo-controlled, sequential MAD study in up to four cohorts (approximately 8 participants per cohort; 6 active, 2 placebo). Participants will receive BLX-7006 or placebo orally once daily for 7 days. Participants will be confined from Day -1 through approximately Day 10 for dosing, safety assessments, and PK/PD sampling, with an EOS visit on Day 14. Dose escalation to subsequent MAD cohorts will occur following review of blinded safety, PK, and PD data by the SRC.
Safety Monitoring:
Safety will be evaluated throughout the study by monitoring adverse events (AEs), clinical laboratory tests, vital signs, 12-lead electrocardiograms (ECGs), and physical examinations. Sentinel dosing and SRC reviews between cohorts are incorporated to minimize risk.
Pharmacokinetic and Pharmacodynamic Assessments:
Blood samples will be collected to characterize single- and multiple-dose PK parameters of BLX-7006, including maximum concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC), half-life (t½), and apparent clearance. PD endpoints will include biomarkers of glucose metabolism and insulin production. The FE part will compare PK parameters between fasted and fed states.
Dose Escalation and Cohort Progression:
The SRC will review cumulative safety, tolerability, PK, and PD data after each cohort before escalating to the next dose level. The number of cohorts may be reduced based on emerging data. The FE and MAD parts may proceed in parallel with later SAD cohorts once predefined safety criteria are met.
The results of this study will provide the initial clinical safety and PK/PD profile of BLX-7006, including preliminary assessment of food effect, to support future clinical development in populations with metabolic diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral BLX-7006 as a single dose (in Part 1 or 2) or once daily for 7 days (in Part 3).
Drug: BLX-7006
Participants will receive an oral placebo that looks like BLX-7006 but does not contain active drug as a single dose (in Part 1 or 2) or once daily for 7 days (in Part 3).
Drug: Placebo
BLX-7006 Single or Multiple doses administered orally as a tablet
Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
Number of participants who experienced Adverse Events (AEs)
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of adverse effects in subjects, as assessed according to CTCAE v5.0. The number of participants who experience an AE will be reported.
Time frame: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Serious Adverse Events (SAEs)
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of SAE in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a SAE will be reported.
Time frame: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Treatment-Related Adverse Avents (TRAEs)
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of TRAEs in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a TRAE will be reported.
Time frame: From first dose through End of Study (up to ~28 days per participant)
Assess maximum observed drug concentration (Cmax)
Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults
Time frame: Up to 14 days after last dose in each cohort
Assess time to maximum concentration (Tmax)
Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults
Time frame: Up to 14 days after last dose in each cohort
Assess the area under the concentration-time curve from time 0 to infinity (AUCinf)
Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults
Time frame: Up to 14 days after last dose in each cohort
Assess the area under the concentration curve from time 0 to the last quantifiable concentration (AUClast)
Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults
Time frame: Up to 14 days after last dose in each cohort
Assess half-life (t½) plasma concentration
Evaluate the relative bioavailability of BLX-7006 in single, food effect, and multiple ascending doses in healthy adults
Time frame: Up to 14 days after last dose in each cohort
Serum fructosamine levels
Evaluate the effect of single and multiple oral doses of BLX-7006 on serum fructosamine levels
Time frame: Up to 14 days after last dose in each cohort
Insulin levels
Evaluate the effect of single and multiple oral doses of BLX-7006 on insulin levels
Time frame: Up to 14 days after last dose in each cohort
C-peptide levels
Evaluate the effect of single and multiple oral doses of BLX-7006 on C-peptide levels
Time frame: Up to 14 days after last dose in each cohort
Glucagon levels
Evaluate the effect of single and multiple oral doses of BLX-7006 on glucagon levels
Time frame: Up to 14 days after last dose in each cohort]
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Apr 2026, 7 months later.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 7 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biolexis Therapeutics